These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16525168)

  • 1. Toward targeted hypertension screening guidelines.
    van Buuren S; Boshuizen HC; Reijneveld SA
    Med Decis Making; 2006; 26(2):145-53. PubMed ID: 16525168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.
    Gaziano TA; Steyn K; Cohen DJ; Weinstein MC; Opie LH
    Circulation; 2005 Dec; 112(23):3569-76. PubMed ID: 16330698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoscopic screening for gastric cancer.
    Dan YY; So JB; Yeoh KG
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hypertension in Finnish general practice seems unsatisfactory despite evidence-based guidelines.
    Varis J; Savola H; Vesalainen R; Kantola I
    Blood Press; 2009; 18(1-2):62-7. PubMed ID: 19353413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifetime health effects and costs of diabetes treatment.
    Niessen LW; Dijkstra R; Hutubessy R; Rutten GE; Casparie AF
    Neth J Med; 2003 Nov; 61(11):355-64. PubMed ID: 14768718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a better yardstick: the choice of treatment thresholds in hypertension.
    McAlister FA; Laupacis A
    Can J Cardiol; 1998 Jan; 14(1):47-51. PubMed ID: 9487272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mass and targeted screening strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and coverage using a cross-sectional survey of 3921 people.
    Lawson KD; Fenwick EA; Pell AC; Pell JP
    Heart; 2010 Feb; 96(3):208-12. PubMed ID: 19737737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of repeat colonoscopy: disparity between guidelines and endoscopists' recommendation.
    Krist AH; Jones RM; Woolf SH; Woessner SE; Merenstein D; Kerns JW; Foliaco W; Jackson P
    Am J Prev Med; 2007 Dec; 33(6):471-8. PubMed ID: 18022063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.